Drug Profile
MaaT 013
Alternative Names: MaaT-013Latest Information Update: 18 Apr 2024
Price :
$50
*
At a glance
- Originator MaaT Pharma
- Developer Assistance Publique Hopitaux de Paris; MaaT Pharma
- Class Antineoplastics; Bacteria; Immunotherapies
- Mechanism of Action Bacteria replacements; Gastrointestinal microbiome modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Graft-versus-host disease
- Phase II Malignant melanoma
- Phase I/II Acute myeloid leukaemia; Myelodysplastic syndromes
Most Recent Events
- 15 Apr 2024 Updated efficacy data from an expanded access program in Graft-versus-host disease released by MaaT Pharma
- 05 Mar 2024 MaaT Pharma completes enrolment in its phase II trial for Malignant melanoma (Inoperable/Unresectable, Late-stage disease, Metastatic disease) in France (Rectal) (NCT04988841)
- 11 Dec 2023 US FDA grants an open-IND with active discussions ongoing with potential clinical investigation sites for MaaT 013